Strongbridge Biopharma (NASDAQ:SBBP) was downgraded by equities research analysts at TheStreet from a “c-” rating to a “d+” rating in a report released on Wednesday, TheStreetRatingsTable reports.
A number of other brokerages have also weighed in on SBBP. ValuEngine lowered Strongbridge Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 1st. Zacks Investment Research raised shares of Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Wednesday, April 17th. Oppenheimer set a $15.00 price target on shares of Strongbridge Biopharma and gave the company a “buy” rating in a report on Tuesday, March 26th. Finally, BidaskClub raised shares of Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a report on Saturday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $13.14.
Shares of Strongbridge Biopharma stock remained flat at $$3.04 during trading on Wednesday. The stock had a trading volume of 40,547 shares, compared to its average volume of 310,629. The stock has a market capitalization of $167.39 million, a price-to-earnings ratio of 9.81 and a beta of 0.17. Strongbridge Biopharma has a 52-week low of $3.01 and a 52-week high of $7.85.
Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.09. The firm had revenue of $4.34 million during the quarter, compared to analyst estimates of $4.69 million. Strongbridge Biopharma had a return on equity of 79.31% and a net margin of 227.79%. Equities research analysts expect that Strongbridge Biopharma will post -1.36 earnings per share for the current year.
Several large investors have recently made changes to their positions in SBBP. Vivo Capital LLC bought a new position in shares of Strongbridge Biopharma in the 1st quarter valued at about $4,552,000. 683 Capital Management LLC lifted its holdings in shares of Strongbridge Biopharma by 183.2% in the 4th quarter. 683 Capital Management LLC now owns 848,700 shares of the biotechnology company’s stock valued at $3,802,000 after acquiring an additional 549,000 shares during the last quarter. Prosight Management LP lifted its holdings in shares of Strongbridge Biopharma by 121.3% in the 4th quarter. Prosight Management LP now owns 937,900 shares of the biotechnology company’s stock valued at $4,202,000 after acquiring an additional 514,054 shares during the last quarter. 22NW LP bought a new position in shares of Strongbridge Biopharma in the 4th quarter valued at about $1,812,000. Finally, Hudson Bay Capital Management LP lifted its holdings in shares of Strongbridge Biopharma by 48.1% in the 4th quarter. Hudson Bay Capital Management LP now owns 1,000,000 shares of the biotechnology company’s stock valued at $4,480,000 after acquiring an additional 324,900 shares during the last quarter. 49.11% of the stock is owned by hedge funds and other institutional investors.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Read More: What are earnings reports?
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.